التفاصيل البيبلوغرافية
| العنوان: |
RadiOnCOVID: Multicentric Analysis of the Impact of COVID-19 on Patients Undergoing Radiation Therapy in Italy. |
| المؤلفون: |
Guerini, Andrea Emanuele, Marvaso, Giulia, Tonoli, Sandro, Corrao, Giulia, Teriaca, Maria Ausilia, Sepulcri, Matteo, Scricciolo, Melissa, Gava, Alessandro, Montrone, Sabrina, Giaj-Levra, Niccolò, Chiorda, Barbara Noris, Mantello, Giovanna, Fiorica, Francesco, Borghesi, Simona, Belgioia, Liliana, Caroli, Angela, Fiorentino, Alba, Jereczek-Fossa, Barbara Alicja, Magrini, Stefano Maria, Buglione, Michela |
| المصدر: |
Cancers; Jan2025, Vol. 17 Issue 1, p86, 11p |
| مصطلحات موضوعية: |
THERAPEUTIC use of antineoplastic agents, CANCER treatment, RADIOTHERAPY, ANTINEOPLASTIC agents, ONCOLOGY, EVALUATION of medical care, CANCER patients, RETROSPECTIVE studies, LONGITUDINAL method, RESEARCH, MEDICAL records, ACQUISITION of data, TUMORS, SPECIALTY hospitals, COVID-19, EVALUATION |
| مصطلحات جغرافية: |
ITALY |
| مستخلص: |
Simple Summary: A study conducted across 19 Italian Radiation Oncology centers examined 41,039 cancer patients undergoing or scheduled for anticancer treatment between February 2020 and May 2021. The study aimed to assess the impact of COVID-19 on treatment schedules and patient outcomes. Among the cohort, 123 patients were diagnosed with COVID-19 during treatment (group A), and 99 were diagnosed before treatment initiation (group B). The overall COVID-19 incidence was 0.54%, including 0.30% in group A. Severe COVID-19 developed in 60 patients, and 45 died due to the infection (incidence of 0.15% and 0.11%, respectively). Treatment delays or suspensions were common, with 37.4% of group A requiring temporary suspension, 32.5% definitive suspension and 37 patients continuing treatment while positive. In group B, 53.5% faced delays, and 20.2% had definitive suspensions. Most of the patients with a COVID-19 diagnosis in our cohort recovered and completed their treatment; nonetheless, the attributable death rate after confirmed infection was 20.27%. With adequate preventive measures, radiation oncology could continue safely during the pandemic, resulting in a low incidence of severe outcomes and mortality. Methods and materials: Patients with ongoing or planned anticancer treatment at 19 Italian Radiation Oncology centers were included in the study retrospectively from 3 February 2020 to 31 December 2020 and prospectively from 1 January 2021 to 31 May 2021. Anonymized data were processed through a specific website and database. Antineoplastic treatment characteristics and timing and outcomes of COVID-19 and its impact on radiotherapy or systemic therapy were described. Results: The retrieved cohort included 41,039 patients that received treatment or were planned for therapy in the study period. Overall, 123 patients had a confirmed COVID-19 diagnosis during antineoplastic treatment (group A) and 99 patients before treatment start (group B). The incidence of COVID-19 across the whole cohort in the index period was 0.54% (groups A + B) and 0.30% considering only group A. A total of 60 patients developed severe COVID-19, and a total of 45 patients died as a consequence of the infection (incidence of 0.15% and 0.11%, respectively). Nonetheless, mortality among COVID-19 patients was high, with an attributable death rate after confirmed infection of 20.27%. Among the 123 patients in group A, 37.4% required temporary treatment suspension, 32.5% definitive suspension and 37 patients continued treatment while positive. As for the 99 patients in group B, 53.5% experienced temporary delay, 20.2% experienced definitive treatment suspension and 26.3% had no delay. Conclusions: Most of the patients with a COVID-19 diagnosis in our cohort recovered and completed their treatment; nonetheless, the attributable death rate after confirmed infection was 20.27%, and mortality was high among cancer patients with severe COVID-19 presentation. The global incidence of death due to COVID-19 or severe COVID-19 was low and decreased over time. Radiation oncology activity could be safely continued during the COVID-19 pandemic with the adoption of adequate preventive measures. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder